# Vir Biotechnology, Inc. clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Vir Biotechnology, Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Vir Biotechnology, Inc.: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/vir-biotechnology-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 27, 2025 | NCT07142811 | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Vir Biotechnology, Inc. | Phase 2 | Active not recruiting | Viral Hepatitis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07142811) |
| August 19, 2025 | NCT07128550 | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | Vir Biotechnology, Inc. | Phase 3 | Active not recruiting | Viral Hepatitis | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128550) |
| May 7, 2025 | NCT06960395 | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Vir Biotechnology, Inc. | Phase 1 | Recruiting | Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06960395) |
| March 30, 2025 | NCT06903338 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Vir Biotechnology, Inc. | Phase 3 | Active not recruiting | Viral Hepatitis | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06903338) |
| May 6, 2023 | NCT05844228 | A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 | Vir Biotechnology, Inc. | Phase 1 | Completed | Renal Impairment | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05844228) |
| November 10, 2022 | NCT05612581 | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection | Vir Biotechnology, Inc. | Phase 1/2 | Completed | Hepatitis B, Chronic | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05612581) |
| October 5, 2022 | NCT05567783 | A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A | Vir Biotechnology, Inc. | Phase 2 | Terminated | Influenza A | 2,977 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05567783) |
| August 2, 2022 | NCT05484206 | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 | Vir Biotechnology, Inc. | Phase 1 | Completed | Hepatic Impairment, Cirrhosis | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05484206) |
| July 18, 2022 | NCT05461170 | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. | Vir Biotechnology, Inc. | Phase 2 | Active not recruiting | Hepatitis D, Chronic | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05461170) |
| May 2, 2022 | NCT05356741 | To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult... | Vir Biotechnology, Inc. | Phase 1/2 | Recruiting | Locally Advanced or Metastatic HER2-Expressing Cancers | 645 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05356741) |
| March 15, 2022 | NCT05280717 | Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) | Vir Biotechnology, Inc. | Phase 1 | Terminated | Covid19 | 316 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05280717) |
| February 11, 2022 | NCT05235347 | Sotrovimab Expanded Access Treatment Protocol (COVID-19) | Vir Biotechnology, Inc. | Not applicable | No longer available | Covid19 | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05235347) |
| August 3, 2021 | NCT04988152 | A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian... | Vir Biotechnology, Inc. | Phase 1 | Completed | Covid19 | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04988152) |
| June 4, 2021 | NCT04913675 | Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. | Vir Biotechnology, Inc. | Phase 3 | Terminated | Covid19 | 1,065 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04913675) |
| April 22, 2021 | NCT04856085 | Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection | Vir Biotechnology, Inc. | Phase 2 | Completed | Hepatitis B, Chronic | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04856085) |
| March 3, 2021 | NCT04779879 | Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate... | Vir Biotechnology, Inc. | Phase 2 | Completed | Covid19 | 354 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04779879) |
| January 27, 2021 | NCT04725877 | VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers | Vir Biotechnology, Inc. | Phase 1 | Completed | HIV I Infection | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04725877) |
| September 10, 2020 | NCT04545060 | VIR-7831 for the Early Treatment of COVID-19 in Outpatients | Vir Biotechnology, Inc. | Phase 2/3 | Completed | Covid19 | 1,057 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04545060) |
| June 9, 2020 | NCT04423393 | Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection | Vir Biotechnology, Inc. | Phase 1 | Completed | Chronic Hepatitis B | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04423393) |
| June 2, 2020 | NCT04412863 | Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection | Vir Biotechnology, Inc. | Phase 2 | Completed | Chronic Hepatitis B | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04412863) |
| July 26, 2019 | NCT04033406 | Study of VIR-2482 in Healthy Volunteers | Vir Biotechnology, Inc. | Phase 1 | Completed | Influenza A | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04033406) |
| September 14, 2018 | NCT03672188 | Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B | Vir Biotechnology, Inc. | Phase 1/2 | Completed | Chronic Hepatitis B | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03672188) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 3 |
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 12 |
| Active not recruiting | 4 |
| Terminated | 3 |
| Recruiting | 2 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis | 9 |
| COVID-19 | 6 |
| Hepatitis B, Chronic | 5 |
| Hepatitis B | 5 |
| Coronavirus Infections | 4 |
| Hepatitis D, Chronic | 4 |
| Hepatitis D | 4 |
| Digestive System Diseases | 2 |
| Liver Diseases | 2 |
| Influenza, Human | 1 |
| Renal Insufficiency | 1 |
| Fibrosis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Biotechnology companies in the United States](https://specstream.ai/data/businesses/biotechnology-companies/united-states)
- [Private investigators in the United States](https://specstream.ai/data/businesses/private-investigators/united-states)
- [Ramen restaurants in the United States](https://specstream.ai/data/businesses/ramen-restaurants/united-states)
- [Sawmills in the United States](https://specstream.ai/data/businesses/sawmills/united-states)
- [Solar installers in the United States](https://specstream.ai/data/businesses/solar-installers/united-states)
- [Surgical supply companies in the United States](https://specstream.ai/data/businesses/surgical-supply-companies/united-states)
